Prescribing of anti-anxiety benzodiazepines was registered in five one month periods in 1989 and 1990 in Moss, a medium-sized Norwegian town. The general practitioners received feed-back on their own prescribing habits and were offered an opportunity to meet colleagues in a self-evaluation group. The results indicate that GPs are influenced by such feed-back, since a reduction in the amount of defined daily doses prescribed was registered. The reduction was mainly a consequence of a change to prescribing a smaller number of pills on each occasion. The authors anticipated a potential reduction in prescribing to elderly persons, but in fact found a substantial reduction in the prescribing of anti-anxiety drugs to young men (with a potential problem of misuse).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Psychotropic medications: a descriptive study of prescription trends in Tabriz, Iran, 2021-2022.
BMC Psychiatry
January 2025
Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Islamic Republic of Iran.
Introduction: Mental disorders, such as anxiety and depression, significantly impacted global populations in 2019 and 2020, with COVID-19 causing a surge in prevalence. They affect 13.4% of the people worldwide, and 21% of Iranians have experienced them.
View Article and Find Full Text PDFPrescribing by level of deprivation in Wales: an investigation of selected medicine groups.
J Epidemiol Community Health
November 2024
Welsh Government, Cardiff, UK.
Background: Prescribing is the most common intervention made by healthcare professionals. Our study aimed to compare prescribing between general practitioner (GP) practices with the highest and lowest levels of deprivation.
Methods: The deprivation level of each GP practice was determined using data from the income domain of the Welsh Index of Multiple Deprivation and individual patient postcodes.
Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis.
J Affect Disord
January 2025
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Background: Beta-blocker prescriptions for patients with anxiety increased substantially between 2003 and 2018, yet there is no clinical guidance concerning their use. A previous review of propranolol - a beta-blocker - in the treatment of anxiety concluded there was insufficient evidence to support its use. Additional data have been published in the eight years since that review including some evidence for other beta-blockers.
View Article and Find Full Text PDFPsychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study.
Lancet Psychiatry
October 2024
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Research Department of Practice and Policy, UCL School of Pharmacy, London, UK; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong, China; School of Pharmacy, Medical Sciences Division, Macau University of Science and Technology, Macau, China; Aston Pharmacy School, Aston University, Birmingham, UK. Electronic address:
Article Synopsis
- A study analyzed how COVID-19 affected psychotropic drug prescriptions among individuals with depressive and anxiety disorders across six countries from 2016 to 2020.
- Researchers used electronic medical records to observe trends in prescribing rates during the pandemic, noting an initial increase followed by a decline towards pre-pandemic levels.
- Most affected patients were aged 45-64, with a significant number of females diagnosed, but data on ethnicity was not collected.
Background: Benzodiazepines have long held a leading position in medical therapeutics, known for their multiple common therapeutic properties and primarily being prescribed for anxiety and insomnia. However, their lack of specificity and various side effects have led to a reevaluation of their long-term use, resulting in a rapid growth in the literature focusing on targeted therapies.
Areas Of Uncertainty: Despite many efforts, uncertainties persist and there are heterogeneous findings across studies regarding the pharmacological effects attributed to gamma-aminobutyric acid type A (GABAA) receptor subunits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!